Status: Recruiting
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Participants needed: 34
Trial details
Phase: Phase 2Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 14, 2026Locations: 1
Eligibility criteria
Relapsed disease: progressive disease (PD) >60 days after cessation of prior the... [+16]
Within 14 days or at least 5 half-lives, whichever is less, of any investigation... [+16]